Adamis Pharmaceuticals

Adamis Pharmaceuticals Net Margin

Delisted

The Net Profit Margin of Adamis Pharmaceuticals (ADMP) as of Nov 15, 2026 is -550.86 %. In the previous year, Net Profit Margin was -1,566.56 % — a change of -64.84% (higher).

Net Margin

-550.86 %

YoY

-64.84%

Last updated:

Net Profit Margin of Adamis Pharmaceuticals is 2022 -550.86 % . Net Profit Margin of Adamis Pharmaceuticals was 2021 -1,566.56 % . It decreases by -64.84% higher compared to the previous year.

Adamis Pharmaceuticals's net margin stands at -550.9%, down from -258.6% several years earlier.

The Adamis Pharmaceuticals Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2010
-22.60 USD
Jan 1, 2016
-300.24 USD
Jan 1, 2017
-195.35 USD
Jan 1, 2018
-258.55 USD
Jan 1, 2019
-132.53 USD
Jan 1, 2020
-298.84 USD
Jan 1, 2021
-1,566.56 USD
Jan 1, 2022
-550.86 USD
The Adamis Pharmaceuticals Net Margin history
YEARNet MarginYoY
-550.86 %-64.84%
-1,566.56 %+424.21%
-298.84 %+125.50%
-132.53 %-48.74%
-258.55 %+32.35%
-195.35 %-34.93%
-300.24 %+1,228.66%
-22.60 %0.00%
-22.60 %+872.31%
-2.32 %-163.92%
3.64 %-1,031.85%
-0.39 %-96.40%
-10.84 %+29.82%
-8.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Adamis Pharmaceuticals Stock analysis

What does Adamis Pharmaceuticals do? Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adamis Pharmaceuticals stock

Net Profit Margin of Adamis Pharmaceuticals is -550.86 % in 2022.

Net Profit Margin of Adamis Pharmaceuticals changed from -1,566.56 % to -550.86 %, representing a -64.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Adamis Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Adamis Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Adamis Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Adamis Pharmaceuticals